Aca­cia Phar­ma's twice spurned drug fi­nal­ly makes the FDA cut

Third time’s the charm for Aca­cia Phar­ma.

The Cam­bridge, UK-based com­pa­ny on Thurs­day fi­nal­ly se­cured FDA ap­proval for its treat­ment for pa­tients with post­op­er­a­tive nau­sea & vom­it­ing (PONV), who are symp­to­matic de­spite hav­ing re­ceived pro­phy­lac­tic treat­ment.

The drug, an in­tra­venous for­mu­la­tion of the se­lec­tive dopamine D2 and D3 an­tag­o­nist amisul­pride, was shown to help pa­tients in four pos­i­tive piv­otal clin­i­cal tri­als by 2017. But man­u­fac­tur­ing trou­bles re­peat­ed­ly hob­bled the com­pa­ny’s quest to get the ther­a­py — brand­ed Barhem­sys — on to the US mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.